Chipotle Mexican Grill’s (NYSE: CMG) shares were up 1.8% in mid-day trade on Thursday after the company announced menu changes that have sparked optimism among analysts about growth in the coming year.
Chipotle said it would roll out a Supergreens salad mix this week which would comprise of hand-cut romaine along with baby kale and baby spinach, replacing the romaine-only salad base. The company also made its grilled, Adobo chicken Whole30 compliant by switching the oil in its marinade.
Chipotle’s Lifestyle Bowls had helped digital sales growth hit the $1 billion milestone recently. The company is innovating and expanding its Lifestyle Bowls and offering free delivery for the whole of January. This strategy is aimed at customers with health-related New Year resolutions and helps stick to various dietary choices such as vegetarian, vegan, keto and paleo.
Last month, Chipotle announced that it is testing a new restaurant design to better support its billion-dollar digital business and that the design will be trialed in four new restaurants.
Chipotle beat revenue and profits estimates in its most recent quarter, recording double-digit growth in both the top and bottom line numbers. The company will report its fourth quarter results on February 4, 2020.
Chipotle’s shares have gained 93% in the past one year.
Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.
Infographic: Highlights of DocuSign’s (DOCU) Q1 2024 results
DocuSign, Inc. (NASDAQ: DOCU), a leading provider of electronic signature solutions, Thursday reported first-quarter earnings. It also provided guidance for the second quarter and fiscal 2024. The company's top line
Macy’s (M): A few points to consider if you have an eye on this retailer
Shares of Macy’s, Inc. (NYSE: M) stayed in red on Thursday. The stock has dropped 22% year-to-date and 32% over the past 12 months. The retailer witnessed sales and profit
Ocean Biomedical’s scientific co-founder Dr. Jonathan Kurtis gets new patent for malaria vaccine
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company focused on clinical programs in oncology, fibrosis, and infectious disease, Thursday said its scientific co-founder Dr. Jonathan Kurtis received a new patent